CY1108395T1 - Ουσια επαυξησης της δρασης εναντι ογκων και παραγοντας εναντι ογκων - Google Patents

Ουσια επαυξησης της δρασης εναντι ογκων και παραγοντας εναντι ογκων

Info

Publication number
CY1108395T1
CY1108395T1 CY20081101101T CY081101101T CY1108395T1 CY 1108395 T1 CY1108395 T1 CY 1108395T1 CY 20081101101 T CY20081101101 T CY 20081101101T CY 081101101 T CY081101101 T CY 081101101T CY 1108395 T1 CY1108395 T1 CY 1108395T1
Authority
CY
Cyprus
Prior art keywords
antitumor
tumor
antitumor effect
administering
enhancing
Prior art date
Application number
CY20081101101T
Other languages
Greek (el)
English (en)
Inventor
Junji Uchida
Koyo Shudo
Original Assignee
Taiho Pharmaceutical Co, Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co, Ltd filed Critical Taiho Pharmaceutical Co, Ltd
Publication of CY1108395T1 publication Critical patent/CY1108395T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CY20081101101T 2003-03-14 2008-10-06 Ουσια επαυξησης της δρασης εναντι ογκων και παραγοντας εναντι ογκων CY1108395T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003070097 2003-03-14
EP04719589A EP1604991B1 (en) 2003-03-14 2004-03-11 Antitumor effect potentiator and antitumor agent

Publications (1)

Publication Number Publication Date
CY1108395T1 true CY1108395T1 (el) 2014-02-12

Family

ID=32984641

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101101T CY1108395T1 (el) 2003-03-14 2008-10-06 Ουσια επαυξησης της δρασης εναντι ογκων και παραγοντας εναντι ογκων

Country Status (21)

Country Link
US (2) US9611227B2 (cg-RX-API-DMAC7.html)
EP (1) EP1604991B1 (cg-RX-API-DMAC7.html)
JP (1) JP4610481B2 (cg-RX-API-DMAC7.html)
KR (1) KR100812693B1 (cg-RX-API-DMAC7.html)
CN (2) CN101357134A (cg-RX-API-DMAC7.html)
AT (1) ATE408408T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004220205B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0408372A (cg-RX-API-DMAC7.html)
CA (1) CA2518195C (cg-RX-API-DMAC7.html)
CY (1) CY1108395T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004016636D1 (cg-RX-API-DMAC7.html)
DK (1) DK1604991T3 (cg-RX-API-DMAC7.html)
ES (1) ES2312978T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA05009781A (cg-RX-API-DMAC7.html)
NZ (1) NZ542150A (cg-RX-API-DMAC7.html)
PL (1) PL1604991T3 (cg-RX-API-DMAC7.html)
PT (1) PT1604991E (cg-RX-API-DMAC7.html)
RU (1) RU2334517C2 (cg-RX-API-DMAC7.html)
SI (1) SI1604991T1 (cg-RX-API-DMAC7.html)
TW (1) TW200503720A (cg-RX-API-DMAC7.html)
WO (1) WO2004081012A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006106984A1 (ja) * 2005-04-01 2006-10-12 Taiho Pharmaceutical Co., Ltd. ピリジン誘導体を有効成分とする放射線治療増強剤
JP4956423B2 (ja) * 2005-04-01 2012-06-20 大鵬薬品工業株式会社 放射線治療増強剤
JPWO2007043531A1 (ja) * 2005-10-07 2009-04-16 セレスター・レキシコ・サイエンシズ株式会社 抗腫瘍剤及び放射線併用療法感受性診断用遺伝子マーカー並びにその利用
AU2008356312B2 (en) 2008-05-12 2015-04-09 Shizuoka Prefecture Antitumor agent, kit, and method for treating cancer
JP5553522B2 (ja) * 2009-03-31 2014-07-16 大鵬薬品工業株式会社 経口投与用医薬組成物
TW201043237A (en) * 2009-04-22 2010-12-16 Taiho Pharmaceutical Co Ltd Method for predicting a therapeutic effect of the chemotherapy for renal cell cancer
CN102309491B (zh) * 2010-07-02 2015-06-10 天津金耀集团有限公司 一种替加氟、吉美斯特复方注射液
WO2012161240A1 (ja) * 2011-05-25 2012-11-29 大鵬薬品工業株式会社 テガフール、ギメラシル、オテラシルカリウム含有有核錠
PL3053578T3 (pl) * 2013-09-30 2021-06-14 Taiho Pharmaceutical Co., Ltd. Skojarzona terapia przeciwnowotworowa z zastosowaniem związku azabicyklicznego
CN106692173A (zh) * 2015-11-18 2017-05-24 北京诺普德医药科技有限公司 一种抗肿瘤复方组合物及其应用
CN106581001B (zh) * 2016-11-03 2018-12-21 江苏恒瑞医药股份有限公司 一种替吉奥组合物的制备方法
KR102258514B1 (ko) 2019-09-23 2021-05-31 연세대학교 산학협력단 신규한 다층형 좌약 제제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69003670T2 (de) 1989-01-05 1994-01-27 Otsuka Pharma Co Ltd Nicht einspritzbares karzinostatisches mittel zur vorbeugung der entzündung durch 5-fluoruracil und verfahren zur behandlung von krebs.
EP0500953B1 (en) * 1990-09-07 1996-08-21 Taiho Pharmaceutical Company Limited Antineoplastic effect potentiator and antineoplastic agent
CA2087540C (en) 1991-05-27 1999-01-19 Taiho Pharmaceutical Co., Ltd. Composition, method and kit for potentiating antitumor activity and for curing tumor
CH683262A5 (it) * 1992-01-22 1994-02-15 Applied Pharma Res Procedimento per la separazione dei diastereomeri del sale di calcio dell'acido (6(R,S)-N-formiltetraidrofolico).
AU2001240001A1 (en) * 2000-03-08 2001-09-17 Bristol-Myers Squibb Company Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
US6770653B2 (en) 2001-03-06 2004-08-03 Bristol-Myers Squibb Company Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
DE60235088D1 (de) * 2001-07-05 2010-03-04 Taiho Pharmaceutical Co Ltd Dna-arrays zur messung der empfindlichkeit gegenüber einem antikrebsmittel

Also Published As

Publication number Publication date
JP4610481B2 (ja) 2011-01-12
PL1604991T3 (pl) 2009-02-27
DK1604991T3 (da) 2009-01-05
EP1604991B1 (en) 2008-09-17
CN101357134A (zh) 2009-02-04
US20170157131A1 (en) 2017-06-08
PT1604991E (pt) 2008-10-27
ATE408408T1 (de) 2008-10-15
RU2005131839A (ru) 2006-02-10
CA2518195C (en) 2009-07-07
BRPI0408372A (pt) 2006-03-21
NZ542150A (en) 2009-09-25
MXPA05009781A (es) 2005-10-26
US9814724B2 (en) 2017-11-14
ES2312978T3 (es) 2009-03-01
CA2518195A1 (en) 2004-09-23
SI1604991T1 (sl) 2009-02-28
AU2004220205B2 (en) 2010-06-17
EP1604991A1 (en) 2005-12-14
RU2334517C2 (ru) 2008-09-27
CN1761665A (zh) 2006-04-19
WO2004081012A1 (ja) 2004-09-23
KR20050106119A (ko) 2005-11-08
KR100812693B1 (ko) 2008-03-13
US20060116345A1 (en) 2006-06-01
DE602004016636D1 (de) 2008-10-30
TWI295173B (cg-RX-API-DMAC7.html) 2008-04-01
AU2004220205A1 (en) 2004-09-23
US9611227B2 (en) 2017-04-04
EP1604991A4 (en) 2006-05-03
JPWO2004081012A1 (ja) 2006-06-08
TW200503720A (en) 2005-02-01

Similar Documents

Publication Publication Date Title
WO2007075554A3 (en) Combination of igfr inhibitor and anti-cancer agent
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
ATE428411T1 (de) Hdl-verstärkende kombinationstherapie-komplexe
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
BR0207443A (pt) Método e forma de dosagem para o tratamento de tumores pela administração de tegafur, uracila, ácido folìnico, paclitaxel e carboplatina
ATE369355T1 (de) Pyrimidinamid derivate und deren verwendung
BRPI0408372A (pt) potencializador de efeito antitumor e agente antitumor
ATE396986T1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
WO2006110175A3 (en) Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor
EA200501166A1 (ru) Составы и способы лечения тромбоцитемии
WO2006110176A3 (en) Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
MY145041A (en) Pyrazolopyrimidine derivatives
TW200603804A (en) Treatment with irinotecan (cpt-11) and an EGFR-inhibitor
BRPI0408238A (pt) anticorpo, método de detectar cáncer, conjunto para detecção de cáncer, e, composição farmacêutica para tratar cáncer
TW200608959A (en) Treatment with oxaliplatin and an egfr-inhibitor
MY140563A (en) Antitumor effect potentiator, antitumor preparation
WO2004052282A3 (en) Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents
CY1106385T1 (el) Χρηση παραγωγων της εποθειλονης για τη θepαπεια του υπepπαραθυρεοειδισμου
DK1572715T3 (da) Steroidforbindelser med antitumor-aktivitet
HK1060518A (en) Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin